William E. Barlow

31.7k total citations · 4 hit papers
277 papers, 19.9k citations indexed

About

William E. Barlow is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, William E. Barlow has authored 277 papers receiving a total of 19.9k indexed citations (citations by other indexed papers that have themselves been cited), including 167 papers in Oncology, 57 papers in Cancer Research and 40 papers in Pulmonary and Respiratory Medicine. Recurrent topics in William E. Barlow's work include Global Cancer Incidence and Screening (68 papers), Breast Cancer Treatment Studies (46 papers) and Colorectal Cancer Screening and Detection (35 papers). William E. Barlow is often cited by papers focused on Global Cancer Incidence and Screening (68 papers), Breast Cancer Treatment Studies (46 papers) and Colorectal Cancer Screening and Detection (35 papers). William E. Barlow collaborates with scholars based in United States, Canada and United Kingdom. William E. Barlow's co-authors include Laura Ichikawa, Richard A. Deyo, Daniel C. Cherkin, Stephen H. Taplin, Karla Kerlikowske, Patricia A. Carney, Andrea Z. LaCroix, Janet Street, Michael VonKorff and Gregory E. Simon and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

William E. Barlow

269 papers receiving 19.1k citations

Hit Papers

Exercise Plus Behavioral ... 1999 2026 2008 2017 2003 2007 1999 2014 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Exercise Plus Behavioral Management in Patients With Alzheimer Disease
    2003 576 citations William E. Barlow et al. profile →
  2. Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System
    2007 558 citations William E. Barlow et al. Journal of Clinical Oncology profile →
  3. Analysis of Case-Cohort Designs
    1999 534 citations William E. Barlow et al. profile →
  4. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
    2014 482 citations Jeffrey B. Smerage, William E. Barlow et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
William E. Barlow 7.6k 3.5k 3.4k 2.4k 2.1k 277 19.9k
Anna N.A. Tosteson 6.1k 0.8× 1.4k 0.4× 3.0k 0.9× 6.9k 2.9× 4.5k 2.1× 348 24.6k
Graham G. Giles 8.6k 1.1× 3.5k 1.0× 4.5k 1.3× 3.3k 1.4× 529 0.3× 778 31.9k
André L. M. Verbeek 3.8k 0.5× 1.5k 0.4× 2.2k 0.7× 1.9k 0.8× 982 0.5× 293 11.8k
Rachel Ballard‐Barbash 10.6k 1.4× 2.5k 0.7× 3.0k 0.9× 1.6k 0.7× 251 0.1× 214 19.8k
Nicholas Day 7.4k 1.0× 2.6k 0.7× 3.0k 0.9× 3.1k 1.3× 342 0.2× 270 26.8k
Anthony B. Miller 8.8k 1.2× 2.6k 0.7× 2.7k 0.8× 1.9k 0.8× 188 0.1× 322 17.4k
Geertruida H. de Bock 5.9k 0.8× 3.0k 0.9× 4.3k 1.3× 1.6k 0.7× 216 0.1× 650 18.7k
Yasuo Ohashi 6.8k 0.9× 1.8k 0.5× 6.7k 2.0× 1.7k 0.7× 391 0.2× 596 23.8k
Michael Pencina 2.0k 0.3× 1.2k 0.3× 3.8k 1.1× 819 0.3× 1.1k 0.5× 330 36.2k
James S. Goodwin 6.9k 0.9× 2.2k 0.6× 4.0k 1.2× 1.2k 0.5× 1.6k 0.7× 442 24.7k

Countries citing papers authored by William E. Barlow

Since Specialization
Citations

This map shows the geographic impact of William E. Barlow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William E. Barlow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William E. Barlow more than expected).

Fields of papers citing papers by William E. Barlow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William E. Barlow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William E. Barlow. The network helps show where William E. Barlow may publish in the future.

Co-authorship network of co-authors of William E. Barlow

This figure shows the co-authorship network connecting the top 25 collaborators of William E. Barlow. A scholar is included among the top collaborators of William E. Barlow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William E. Barlow. William E. Barlow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Winchester, David J., Stephen B. Edge, Kimberly H. Allison, et al.. (2025). Novel Postneoadjuvant Prognostic Breast Cancer Staging System. Journal of Clinical Oncology. 43(17). 1948–1960. 3 indexed citations
2.
Unger, Joseph M., Cathee Till, Catherine M. Tangen, et al.. (2024). Long-Term Adverse Effects and Complications After Prostate Cancer Treatment. JAMA Oncology. 10(12). 1654–1654. 9 indexed citations
3.
4.
Bardia, Aditya, Lajos Pusztai, Kathy S. Albain, et al.. (2024). TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic Advances in Medical Oncology. 16. 12693072–12693072. 16 indexed citations
5.
Hershman, Dawn L., Riha Vaidya, Cathee Till, et al.. (2024). Socioeconomic Deprivation and Health Care Use in Patients Enrolled in SWOG Cancer Clinical Trials. JAMA Network Open. 7(3). e244008–e244008. 5 indexed citations
6.
Jagsi, Reshma, William E. Barlow, Wendy A. Woodward, et al.. (2023). Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA Oncology. 9(8). 1083–1083. 6 indexed citations
7.
Onega, Tracy, Elisabeth F. Beaber, Jennifer S. Haas, et al.. (2023). Screening Beyond the Evidence: Patterns of Age and Comorbidity for Breast, Cervical, and Colorectal Cancer Screening. Journal of General Internal Medicine. 39(8). 1324–1331. 3 indexed citations
8.
Zirpoli, Gary, William E. Barlow, G. Thomas Budd, et al.. (2023). Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. Journal of the National Comprehensive Cancer Network. 21(11). 1172–1180.e3. 15 indexed citations
9.
Speers, Corey, W. Fraser Symmans, William E. Barlow, et al.. (2023). Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. Journal of Clinical Oncology. 41(10). 1841–1848. 9 indexed citations
10.
Hershman, Dawn L., Aasthaa Bansal, William E. Barlow, et al.. (2023). Intervention Nonadherence in the TrACER (S1415CD) Study: A Pragmatic Randomized Trial of a Standardized Order Entry for CSF Prescribing. JCO Oncology Practice. 19(12). 1160–1167. 1 indexed citations
11.
Hershman, Dawn L., Aasthaa Bansal, Sean D. Sullivan, et al.. (2022). A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia. Journal of Clinical Oncology. 41(3). 590–598. 3 indexed citations
12.
Chubak, Jessica, Andrea N. Burnett‐Hartman, William E. Barlow, et al.. (2022). Estimating Cancer Screening Sensitivity and Specificity Using Healthcare Utilization Data: Defining the Accuracy Assessment Interval. Cancer Epidemiology Biomarkers & Prevention. 31(8). 1517–1520. 6 indexed citations
13.
Powles, Ryan L., Vikram B. Wali, Xiaotong Li, et al.. (2020). Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome. Clinical Cancer Research. 26(8). 1977–1984. 9 indexed citations
14.
Hershman, Dawn L., Cathee Till, Jason D. Wright, et al.. (2020). Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials. Breast Cancer Research and Treatment. 181(2). 455–463. 5 indexed citations
15.
Paoletti, Costanza, Jieling Miao, Elizabeth P. Darga, et al.. (2019). Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. Clinical Cancer Research. 25(20). 6089–6097. 57 indexed citations
16.
Chen, Lü, Jessica Chubak, Denise M. Boudreau, et al.. (2017). Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER–Medicare Population. Cancer Epidemiology Biomarkers & Prevention. 26(11). 1603–1610. 27 indexed citations
17.
Chen, Lu, Jessica Chubak, Denise M. Boudreau, et al.. (2017). Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis. Cancer Research. 77(21). 6033–6041. 32 indexed citations
18.
Conant, Emily F., Elisabeth F. Beaber, Brian L. Sprague, et al.. (2016). Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium. Breast Cancer Research and Treatment. 156(1). 109–116. 146 indexed citations
19.
Beaber, Elisabeth F., Kathleen E. Malone, Mei-Tzu C. Tang, et al.. (2014). Oral Contraceptives and Breast Cancer Risk Overall and by Molecular Subtype Among Young Women. Cancer Epidemiology Biomarkers & Prevention. 23(5). 755–764. 53 indexed citations
20.
Poznak, Catherine Van, Sarah Temin, Gary C. Yee, et al.. (2011). American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer. Journal of Clinical Oncology. 29(9). 1221–1227. 235 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna N.A. Tosteson Breakdown of academic impact, for papers by Graham G. Giles Breakdown of academic impact, for papers by André L. M. Verbeek Breakdown of academic impact, for papers by Rachel Ballard‐Barbash Breakdown of academic impact, for papers by Nicholas Day Breakdown of academic impact, for papers by Anthony B. Miller Breakdown of academic impact, for papers by Geertruida H. de Bock Breakdown of academic impact, for papers by Yasuo Ohashi Breakdown of academic impact, for papers by Michael Pencina Breakdown of academic impact, for papers by James S. Goodwin
Rankless by CCL
2026